Veloxis v. Accord Healthcare & Intas: Tacrolimus Patent Consent Judgment
Veloxis Pharmaceuticals secured a consent judgment and permanent injunction against Accord Healthcare and Intas Pharmaceuticals, blocking generic entry of ENVARSUS XR® tacrolimus under ANDA No. 217255. The case, filed in Delaware in July 2022, resolved in January 2024 across seven asserted patents — with no costs awarded to either party.
Pharma ANDA dispute ends in permanent injunction for Veloxis
Veloxis Pharmaceuticals, Inc. filed this Hatch-Waxman patent infringement action on 7 July 2022 in the District of Delaware against Accord Healthcare, Inc. and its parent Intas Pharmaceuticals, Ltd. The dispute centred on Accord’s Abbreviated New Drug Application (ANDA) No. 217255, which sought FDA approval to market generic 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets — a direct generic version of Veloxis’s branded immunosuppressant ENVARSUS XR®. Veloxis asserted seven U.S. patents covering the formulation and its clinical use.
The case concluded on 24 January 2024 when the parties entered a stipulated consent judgment. Under its terms, Accord and Intas are permanently enjoined from making, using, selling, offering to sell, importing, or distributing the ANDA product until expiry of all seven patents-in-suit. All claims and counterclaims were dismissed with prejudice, with each party bearing its own costs. Notably, the consent judgment preserves Accord’s Paragraph IV certification and does not prevent the FDA from approving ANDA No. 217255 — meaning approval may proceed, but commercialisation remains blocked.
Resolution after approximately 18 months is broadly consistent with the pace of negotiated outcomes in Hatch-Waxman cases, where early consent judgments frequently signal that the ANDA filer could not mount a credible invalidity or non-infringement defence, or that the commercial calculus favoured settlement over prolonged litigation. The public record does not disclose whether any licensing arrangement or future entry date was agreed privately. The seven-patent assertion — spanning formulation, dosing and manufacturing claims — suggests Veloxis constructed a layered IP barrier around ENVARSUS XR® that would have been difficult to design around.
Filing to filing in 566 days
Days from filing to consent judgment (July 2022 – January 2024)
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Veloxis Pharmaceuticals, Inc. | Company | Specialty pharma company — holder of ENVARSUS XR® tacrolimus extended-release patentsSearch in Eureka ↗ |
| Defendant | Accord Healthcare, Inc. | Company | Accord Healthcare, Inc. (US subsidiary of Intas Pharmaceuticals, Ltd.) — ANDA generic drug filerSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Veloxis Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Aaron F. Barkoff | Attorney | Counsel for Accord Healthcare, Inc.Search in Eureka ↗ |
| Defendant counsel | Alejandro J. Menchaca | Attorney | Counsel for Accord Healthcare, Inc.Search in Eureka ↗ |
| Defendant counsel | Ben J. Mahon | Attorney | Counsel for Accord Healthcare, Inc.Search in Eureka ↗ |
| Defendant counsel | Kelly E. Farnan | Attorney | Counsel for Accord Healthcare, Inc.Search in Eureka ↗ |
| Defendant counsel | Sara M. Metzler | Attorney | Counsel for Accord Healthcare, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Unassigned | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The consent judgment’s phrasing — enjoining Accord and Intas ‘until expiration of the Patents-in-Suit’ — creates a broad, portfolio-wide bar rather than patent-by-patent relief. The explicit injunction against third-party assistance extends liability beyond the named defendants. Critically, the preservation of the FDA approval pathway and Paragraph IV certification in paragraphs 7–8 reflects standard Hatch-Waxman negotiating practice, and should be read as a strategic placeholder, not a concession by Veloxis.
US8685998B2 and six continuation patents — extended-release tacrolimus
The seven patents-in-suit collectively protect the extended-release formulation of tacrolimus — an immunosuppressant used to prevent organ rejection following kidney transplantation — as embodied in Veloxis’s ENVARSUS XR® product. The pioneer patent, US8685998B2 (application US12/499034), anchors the family, with subsequent continuations (US9549918B2, US10166190B2, US10864199B2, US11110081B2, US11123331B2, and US11419823) extending coverage across formulation variants, dosing methods, and manufacturing processes. The staggered application dates across multiple application numbers suggest a deliberate strategy to maximise patent term and coverage breadth.
For the transplant immunosuppressant sector, this patent portfolio represents one of the more defensively structured estates in specialty pharma. Tacrolimus’s narrow therapeutic index — where small concentration differences can mean toxicity or rejection — makes the extended-release formulation clinically distinctive and commercially important. Any generic entrant must navigate all seven patents simultaneously, making a successful design-around or IPR challenge significantly more resource-intensive than a single-patent ANDA dispute. Competitors in the transplant drug space should treat this case as a reference point for the IP barriers defending once-daily tacrolimus formulations.
Should your R&D team run an FTO against the ENVARSUS XR® patent family?
Any company developing extended-release tacrolimus formulations — whether for transplantation, autoimmune indications, or biosimilar-adjacent programmes — should treat the seven Veloxis patents as a live FTO risk. The consent judgment confirms these patents have not been invalidated by a direct challenger. The fact that Accord retained its Paragraph IV certification suggests the generic industry has not abandoned interest, but also that no successful invalidity argument has yet prevailed. Product teams filing or planning ANDAs in this space should commission claim-level FTO analysis before submitting.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map each claim of US8685998B2 and its six continuation patents against proposed formulation approaches, flagging literal and doctrine-of-equivalents risk at the claim level. Eureka’s claim monitoring tools can also alert you to any new continuation filings or reissue applications in the Veloxis tacrolimus family — ensuring your FTO remains current as the portfolio evolves.
Run a freedom-to-operate analysis on US10864199B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA patent cases in immunosuppressants and specialty pharma
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the tacrolimus and transplant drug IP landscape
A seven-patent consent injunction reinforces Veloxis’s dominance over ENVARSUS XR® and sets a clear warning for other generic ANDA filers in this category.
Consent judgments in ANDA cases often mask unlicensed entry agreements
When ANDA defendants agree to a consent injunction without a public settlement disclosure, it typically signals one of two outcomes: the generic filer lacked a viable invalidity argument, or a private authorised generic or future entry date deal was reached. The public record here is silent on the latter — practitioners monitoring ENVARSUS XR® competition should track Accord’s ANDA approval status and any future launch activity as a proxy.
Seven-patent portfolios are the standard defence posture in transplant immunosuppressants
Veloxis’s approach — staggering patent filings across formulation, dosing, and continuation families — is consistent with best practice in specialty pharma IP. R&D teams developing extended-release immunosuppressant generics should expect comparable portfolio depth from other branded holders in this category and plan FTO analysis accordingly, well before ANDA submission.
Veloxis v Accord — key questions answered
The case resolved on 24 January 2024 via a consent judgment entered by the Delaware District Court. Accord Healthcare and Intas Pharmaceuticals were permanently enjoined from commercialising their generic tacrolimus ANDA product (ANDA No. 217255) until expiry of all seven Veloxis patents-in-suit. All claims were dismissed with prejudice and no costs were awarded.
Veloxis asserted seven U.S. patents: US8685998B2, US9549918B2, US10166190B2, US10864199B2, US11110081B2, US11123331B2, and US11419823. These patents collectively cover the extended-release tacrolimus formulation and related methods of use that underpin the ENVARSUS XR® product.
The consent judgment permanently enjoins Accord and Intas from commercialising their ANDA product until all seven patents expire. However, the judgment preserves Accord’s Paragraph IV certification and does not prevent FDA from approving ANDA No. 217255 — meaning Accord could launch if any patent is later invalidated through PTAB or other proceedings, without needing to refile for FDA approval.
Delaware District Court is the predominant venue for Hatch-Waxman ANDA patent litigation in the United States. Veloxis filed there consistent with standard practice for branded pharmaceutical companies, as the court has extensive experience with pharmaceutical patent disputes and Accord Healthcare is incorporated in Delaware.
ANDA No. 217255 is Accord Healthcare’s Abbreviated New Drug Application seeking FDA approval to market generic extended-release tacrolimus tablets in 0.75 mg, 1 mg, and 4 mg strengths — a direct generic version of Veloxis’s ENVARSUS XR®. The consent judgment blocks Accord from commercialising this product until the Veloxis patent portfolio expires.
PatSnap Eureka searches patents and litigation data to answer instantly.